Skip to main content
TYK Medicines, Inc logo

TYK Medicines, Inc — Investor Relations & Filings

Ticker · 2410 ISIN · CNE100006L34 HKEX Manufacturing
Open in API
Filings indexed 870 across all filing types
Latest filing 2025-02-03 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2410

About TYK Medicines, Inc

https://www.tykmedicines.com

TYK Medicines, Inc. is a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of innovative small-molecule targeted therapies. The company leverages a proprietary small molecule drug design and screening platform, with a primary strategic focus on oncology, particularly treatments for lung cancer. The lead pipeline asset, TY-9591 (Edotamidine mesylate), an EGFR-targeted therapy, is currently in the Pre-NDA stage, having demonstrated promising clinical efficacy in treating lung cancer patients with brain metastasis. The pipeline also includes assets such as TY-302 and TY-2136, alongside multiple CDK inhibitors in clinical development, reflecting a commitment to addressing unmet medical needs in targeted cancer treatment.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2025
Regulatory Filings Classification · 90% confidence The document is an FF301 Monthly Return for Equity Issuer and Hong Kong Depositary Receipts submitted to the Hong Kong Exchange detailing movements in issued shares and treasury shares for the month ended 31 January 2025. It is a recurring regulatory filing under the Exchange Listing Rules rather than a standalone capital event notice or financial report. It does not fit into specific categories like share issuance (SHA) or own share transactions (POS) since no actual repurchase or issuance occurred this month, and it is clearly a mandated monthly submission. Therefore it best fits the ‘Regulatory Filings’ fallback category (RNS).
2025-02-03 English
CHANGE OF SHARE REGISTRAR AND TRANSFER OFFICE
Regulatory Filings Classification · 82% confidence The document is a corporate announcement filed on the Hong Kong Stock Exchange regarding the operational change of the company’s share registrar and transfer office. It is not a financial report, board appointment, M&A notice, dividend, or capital change. It does not attach or publish a separate report, so it is not an RPA. This is a general regulatory announcement disclosing a corporate secretarial change. Therefore it falls under the fallback “Regulatory Filings” category (RNS).
2025-01-15 English
ARTICLES OF ASSOCIATION
Governance Information Classification · 95% confidence The document is titled “Articles of Association” and contains the company’s internal governance provisions: share issuance, board structure, shareholder meeting rules, senior management duties, accounting system, amendments procedures, etc. It is the company’s constitution/bylaws, detailing governance policies rather than financial results, capital market transactions, or meeting announcements. This clearly aligns with Governance Information (CGR).
2025-01-03 English
POLL RESULTS OF 2025 FIRST EXTRAORDINARY GENERAL MEETING HELD ON JANUARY 3, 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an official announcement by TYK Medicines of the poll results from its 2025 first extraordinary general meeting (EGM), detailing vote counts and resolutions passed. This aligns precisely with the definition of a Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2025-01-03 English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 December 2024
Regulatory Filings Classification · 85% confidence The document is a mandatory monthly securities movement return (FF301) submitted to the Hong Kong Exchange under Chapter 19B of the Listing Rules. It provides share capital and issued share movement details for the month ending 31 December 2024. This is not an earnings release, share issuance announcement, or financial report, but rather a routine regulatory filing. Therefore it falls under the general Regulatory Filings category (RNS).
2025-01-03 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2024
Regulatory Filings Classification · 87% confidence The document is the HKEX FF301 “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts” under Chapter 19B of the Exchange Listing Rules. It is a periodic regulatory submission detailing share capital and movements in issued shares, not an annual or interim financial report, earnings release, or corporate action announcement. This type of submission is a general regulatory filing to the exchange. Therefore, it falls under the fallback category "Regulatory Filings (RNS)."
2025-01-02 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.